Olema Pharmaceuticals Inc (OLMA): Hedge Fund Ownership & Smart Money Signals (Q1 2026)

Q: Is it too late to buy Olema Pharmaceuticals Inc (OLMA) following the 2026 Q1 hedge fund 13F filings?

As of today, OLMA has moved -32.4% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.9% for the XLV sector ETF — an outperformance of -36.3%. Since the quarter end (March 31, 2026), OLMA gained -38.4% vs +2.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Olema Pharmaceuticals Inc (OLMA)

198 + Investors. Track Smart Money conviction in OLMA. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — OLMA

Based on 198 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q

For 1 consecutive quarter, more hedge funds reduced or closed their OLMA positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

🏔️

At the ownership peak (98% of max)

98% of all-time peak

198 hedge funds hold OLMA right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +50% more funds vs a year ago

fund count last 6Q

+66 new funds entered over the past year (+50% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟡

Slight buying edge — 54% buying

125 buying108 selling

Last quarter: 125 funds bought or added vs 108 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

⚠️

Fewer new buyers each quarter (-43 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 17 → 21 → 89 → 46. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

📌

Mixed — 36% long-term, 33% new

■ 36% conviction (2yr+) ■ 31% medium ■ 33% new

Of the 198 current holders: 72 (36%) held >2 years, 61 held 1–2 years, and 65 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

💎

Buying through price weakness — shares +13%, value -33%

Value

-33%

+13%

Last quarter: funds added +13% more shares while total portfolio value only changed -33%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.

🚀

Acceleration phase — new buyers rushing in

26 → 17 → 21 → 89 → 46 new funds/Q

New funds entering each quarter: 17 → 21 → 89 → 46. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.

🏛️

Deep conviction — 52% of holders stayed 2+ years

■ 52% veterans ■ 16% 1-2yr ■ 32% new

Of 217 current holders: 113 (52%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.

✅

Strong quality — 36% AUM from major funds

36% from top-100 AUM funds

47 of 198 holders rank in the top 100 by AUM, accounting for 36% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

4.9

out of 10

Moderate Exit Risk

Exit risk score 4.9/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	198	202	-1.98%
13F Shares	105M	92M	13.3%
Total Value	$1.53B	$2.28B	-33.06%
New Positions	46	89	-43
Increased Positions	76	60	+16
Closed Positions	50	12	+38
Reduced Positions	50	37	+13
Total Calls	17	8	112.5%
Total Puts	8	5	60.0%
PUT/CALL Ratio	0.47	0.62	Bullish

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

198

202

-1.98%

13F Shares

105M

92M

13.3%

Total Value

$1.53B

$2.28B

-33.06%

New Positions

-43

Increased Positions

+16

Closed Positions

+38

Reduced Positions

+13

Total Calls

112.5%

Total Puts

60.0%

PUT/CALL Ratio

0.47

0.62

Bullish

Institutional Holders (2026 Q1)

198 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in OLMA. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 OLMA holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Bain Capital Life Sciences Investors, LLC	10.05%	7,473,238	$111.4M
2	Defilade Capital Management, L.P.	3.15%	1,504,536	$22.4M
3	Cormorant Asset Management, LP	2.92%	3,900,000	$58.1M
4	Bvf Inc/Il	2.52%	5,295,893	$79.0M
5	Paradigm Biocapital Advisors LP	2.44%	8,020,576	$119.6M
6	Logos Global Management LP	2.39%	3,208,875	$47.8M
7	Lightspeed Management Company, L.L.C.	2.05%	1,355,299	$20.2M
8	Siren, L.L.C.	1.97%	4,756,949	$70.9M
9	Birchview Capital, LP	1.86%	219,000	$3.3M
10	Kingdon Capital Management, L.L.C.	1.40%	855,000	$12.7M
11	First Turn Management, LLC	1.28%	768,662	$11.5M
12	Vivo Capital, LLC	0.84%	671,843	$10.0M
13	Ikarian Capital, LLC	0.72%	598,281	$8.9M
14	Ikarian Capital, LLC	0.67%	549,800	$8.2M
15	HighVista Strategies LLC	0.48%	117,601	$1.8M
16	Ra Capital Management, L.P.	0.41%	2,600,000	$38.8M
17	Cormorant Asset Management, LP	0.37%	500,000	$7.5M
18	Pier Capital, LLC	0.33%	136,108	$2.0M
19	Act Capital Management, LLC	0.29%	25,000	$373K
20	Hennion & Walsh Asset Management, Inc.	0.24%	481,485	$7.2M
21	Portland Investment Counsel INC.	0.24%	50,000	$746K
22	Sphera Funds Management LTD.	0.24%	100,000	$1.5M
23	Diadema Partners LP	0.21%	84,000	$1.3M
24	Vestal Point Capital, LP	0.18%	428,551	$6.4M
25	Optimize Financial Inc	0.15%	20,567	$307K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Olema Pharmaceuticals Inc (OLMA)

What does the Smart Money Trend signal show for OLMA?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their OLMA positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for OLMA?

Slight buying edge — 54% buying: Last quarter: 125 funds bought or added vs 108 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for OLMA holders?

Strong quality — 36% AUM from major funds: 47 of 198 holders rank in the top 100 by AUM, accounting for 36% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held OLMA?

Mixed — 36% long-term, 33% new: Of the 198 current holders: 72 (36%) held >2 years, 61 held 1–2 years, and 65 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Olema Pharmaceuticals Inc (OLMA) following the 2026 Q1 hedge fund 13F filings?

As of today, OLMA has moved -32.4% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.9% for the XLV sector ETF — an outperformance of -36.3%. Since the quarter end (March 31, 2026), OLMA has gained -38.4% vs +2.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Olema Pharmaceuticals Inc (OLMA)

Smart Money Signals — OLMA

Selling streak — 1 quarter in a row

At the ownership peak (98% of max)

Fast accumulation — +50% more funds vs a year ago

Slight buying edge — 54% buying

Fewer new buyers each quarter (-43 vs last Q)

Mixed — 36% long-term, 33% new

Buying through price weakness — shares +13%, value -33%

Acceleration phase — new buyers rushing in

Deep conviction — 52% of holders stayed 2+ years

Strong quality — 36% AUM from major funds

Institutional Sentiment Summary — OLMA

Hedge Fund Ownership: OLMA

Market Analysis: OLMA

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: OLMA

Is It Too Late to Buy Olema Pharmaceuticals Inc (OLMA) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: OLMA

Statistics: OLMA

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q1)

Frequently Asked Questions — Olema Pharmaceuticals Inc (OLMA)

Welcome to 13Foresight!